{"data":[{"id":"c3311ce3-ca1b-4a42-84ed-5f0a3774982a","theory_name":"RNAi gene silencing treats disease at its source","theory_summary":null,"theory_text":"Alnylam's core causal theory is that many diseases can be modified by selectively preventing production of proteins that cause or contribute to pathology. Small interfering RNA therapeutics harness the endogenous RNA interference pathway to degrade target mRNA, reducing expression of disease-driving genes before harmful proteins are made.\n\nThe testable prediction is that durable, specific knockdown of a validated pathogenic transcript should reduce the downstream protein, improve disease biomarkers, and translate into clinical benefit across diseases where the target protein is causal or strongly contributory.","source_url":"https://alnylam.com/alnylam-rnai-pipeline","source_type":"company_website","is_primary":true,"extracted_at":"2026-06-29 00:39:37.92851+00","owner":{"kind":"company","name":"Alnylam","public_id":"7dLxPoQV","public_url":"https://eternalsearch.net/companies/7dLxPoQV"},"evaluation":{"popperian_sum":34,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/c3311ce3-ca1b-4a42-84ed-5f0a3774982a"},{"id":"cfadc238-a34a-4221-8aa8-817aa9149dc3","theory_name":"Telomere dysfunction and cellular senescence","theory_summary":null,"theory_text":"Senescence.info describes telomere shortening as a causal mechanism of replicative cellular senescence: because linear chromosome ends shorten with cell division, critically short or uncapped telomeres are recognized as DNA damage and activate p53/p21 and pRb pathways that arrest the cell cycle. Telomerase can elongate telomeres, bypass replicative senescence in human cells, and reverse some pre-senescent cell functions in vitro.\n\nThe theory predicts that telomere length or capping state should track replicative capacity in relevant human cells, that restoring telomerase or telomere stability should delay cellular senescence, and that dysfunctional telomeres should activate DNA damage signaling and growth arrest. It also predicts a cancer tradeoff because telomere maintenance is required for immortal cell proliferation.","source_url":"https://senescence.info/blog-pages/gerontology-information/telomeres-and-telomerase.html","source_type":"company_website","is_primary":false,"extracted_at":"2026-06-24 14:57:01.750268+00","owner":{"kind":"company","name":"Senescence.info","public_id":"lF3j9ulv","public_url":"https://eternalsearch.net/companies/lF3j9ulv"},"evaluation":{"popperian_sum":34,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":0,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/cfadc238-a34a-4221-8aa8-817aa9149dc3"},{"id":"1bf302dc-9edc-4b5c-b2e3-c016785e2b76","theory_name":"TTR stabilization blocks ATTR-CM amyloid cardiotoxicity","theory_summary":null,"theory_text":"BridgeBio's ATTR-CM theory is that transthyretin tetramer destabilization causes TTR proteins to misfold, aggregate into amyloid fibrils, and accumulate in the heart, producing progressive cardiomyopathy, hospitalization risk, and mortality. Acoramidis is intended to bind and stabilize TTR, reducing the upstream supply of misfolded amyloidogenic protein.\n\nTestable predictions are that acoramidis should increase serum TTR and measured TTR stabilization, slow cardiac disease progression, preserve function and quality of life, and reduce all-cause mortality and cardiovascular hospitalizations in ATTR-CM patients compared with placebo.","source_url":"https://eidostx.com/science/attr-cm","source_type":"company_website","is_primary":true,"extracted_at":"2026-07-02 13:02:48.289976+00","owner":{"kind":"company","name":"Eidos Therapeutics","public_id":"KJEsxKQd","public_url":"https://eternalsearch.net/companies/KJEsxKQd"},"evaluation":{"popperian_sum":33,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":7,"dimensions":{"ambition":7,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":13,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":19},"detail_url":"https://eternalsearch.net/api/v1/theories/1bf302dc-9edc-4b5c-b2e3-c016785e2b76"},{"id":"5f9a5921-ce8a-43f1-b5f9-649a4e4823ab","theory_name":"OSKM dosing window separates rejuvenation from dedifferentiation risk","theory_summary":null,"theory_text":"The company's stated research plan treated OSKM factor exposure as a dose- and timing-sensitive intervention: too little exposure would fail to meaningfully reset age-associated epigenetic marks, while excessive or poorly controlled exposure could push cells toward pluripotency and create safety risks. The causal claim is that there exists a therapeutic window where partial reprogramming rejuvenates cells while preserving differentiated cell identity.\n\nThe testable prediction is that systematic optimization of OSKM dose, duration, periodicity, and tissue targeting should identify regimens that improve rejuvenation or regeneration readouts without inducing uncontrolled proliferation, dedifferentiation, or tumorigenesis.","source_url":"https://www.fightaging.org/archives/2017/10/an-interview-with-yuri-deigin-of-youthereum-genetics-the-merging-of-an-initial-coin-offering-and-pluripotency-factors/","source_type":"interview","is_primary":false,"extracted_at":"2026-07-02 04:25:16.413234+00","owner":{"kind":"company","name":"Youthereum Genetics","public_id":"RMlfk1NG","public_url":"https://eternalsearch.net/companies/RMlfk1NG"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":1,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":12},"detail_url":"https://eternalsearch.net/api/v1/theories/5f9a5921-ce8a-43f1-b5f9-649a4e4823ab"},{"id":"14a23359-a8f8-424e-bad0-4921f7e683a5","theory_name":"Telomere transfer rescues T cells from senescence","theory_summary":null,"theory_text":"Sentcell's telomere-transfer theory is that some antigen-specific T cells avoid senescence not primarily by telomerase activation, but by acquiring telomere vesicles from antigen-presenting cells at the immunological synapse. APCs degrade shelterin, cleave telomeres via TZAP, package telomere material into extracellular vesicles, and transfer those vesicles to T cells, where Rad51 enables fusion with chromosome ends.\n\nThe prediction is that telomere-acquiring T cells should lengthen telomeres independently of telomerase, resist senescence before clonal expansion, and generate longer-lasting immunological memory than comparable T cells that do not receive telomere vesicles.","source_url":"https://doi.org/10.1038/s41556-022-00991-z","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 12:42:11.592046+00","owner":{"kind":"company","name":"Sentcell","public_id":"0ziFdo70","public_url":"https://eternalsearch.net/companies/0ziFdo70"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":8,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":8,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":2,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":21},"detail_url":"https://eternalsearch.net/api/v1/theories/14a23359-a8f8-424e-bad0-4921f7e683a5"},{"id":"97d80213-e2d7-4bdc-8594-58ea33d85e84","theory_name":"GalNAc-siRNA delivery enables durable liver-targeted therapy","theory_summary":null,"theory_text":"Alnylam's platform theory includes the claim that chemically stabilized siRNAs conjugated to N-acetylgalactosamine ligands can be delivered efficiently to the liver, enabling potent and durable knockdown of hepatic disease targets. This delivery mechanism is presented as a key reason RNAi therapeutics can move from rare diseases into widespread chronic conditions.\n\nThe testable prediction is that GalNAc-conjugated siRNAs should achieve durable target mRNA and protein reduction after infrequent dosing, with sufficient specificity and potency to affect chronic disease biomarkers and outcomes where the liver-produced target is causal.","source_url":"https://pubmed.ncbi.nlm.nih.gov/38409587/","source_type":"publication","is_primary":false,"extracted_at":"2026-06-29 00:39:37.99452+00","owner":{"kind":"company","name":"Alnylam","public_id":"7dLxPoQV","public_url":"https://eternalsearch.net/companies/7dLxPoQV"},"evaluation":{"popperian_sum":33,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":7,"dimensions":{"ambition":7,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":12},"detail_url":"https://eternalsearch.net/api/v1/theories/97d80213-e2d7-4bdc-8594-58ea33d85e84"},{"id":"1af2112d-ff4d-45b4-98ff-efe280e35780","theory_name":"TTR knockdown slows ATTR cardiomyopathy progression","theory_summary":null,"theory_text":"For transthyretin amyloidosis with cardiomyopathy, the causal theory is that hepatic transthyretin production drives amyloid deposition and progressive cardiac dysfunction. Vutrisiran uses RNA interference to inhibit liver production of transthyretin, which should lower circulating TTR, reduce ongoing amyloid burden, and thereby slow functional decline and cardiovascular events in ATTR-CM.\n\nThe clinical prediction is that sustained TTR reduction should reduce death and recurrent cardiovascular events while preserving walking capacity and health-related quality of life compared with placebo.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39213194/","source_type":"publication","is_primary":false,"extracted_at":"2026-06-29 00:39:37.944443+00","owner":{"kind":"company","name":"Alnylam","public_id":"7dLxPoQV","public_url":"https://eternalsearch.net/companies/7dLxPoQV"},"evaluation":{"popperian_sum":33,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":7,"dimensions":{"ambition":7,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":14},"detail_url":"https://eternalsearch.net/api/v1/theories/1af2112d-ff4d-45b4-98ff-efe280e35780"},{"id":"9f482295-7d78-46d0-a53b-cd5a68d5039f","theory_name":"Scaffold-plus-stem-cell neurorepair after spinal cord injury","theory_summary":null,"theory_text":"UC Irvine-associated work proposes that spinal cord injury recovery can be improved by combining an acute multichannel PLG scaffold bridge with later human neural stem cell transplantation. The scaffold is described as mechanically stabilizing the lesion, modulating inflammation, and creating a permissive channelized environment for axonal regrowth; the transplanted neural stem cells then migrate into the bridge and host cord, differentiate into myelinating oligodendrocytes and synaptically integrated neurons, and improve the function of newly regenerated connections.\n\nTestable predictions are that combination treatment should increase regenerating axons, increase myelinated axons within the bridge, support synaptic reconnection between motor cortex and forelimb muscle circuitry, and improve locomotor recovery versus scaffold or cell therapy alone.","source_url":"https://pubmed.ncbi.nlm.nih.gov/38499577/","source_type":"publication","is_primary":true,"extracted_at":"2026-06-27 08:30:48.090413+00","owner":{"kind":"company","name":"Memory Air","public_id":"BBBEaHZV","public_url":"https://eternalsearch.net/companies/BBBEaHZV"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":8,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":8,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":6,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":20},"detail_url":"https://eternalsearch.net/api/v1/theories/9f482295-7d78-46d0-a53b-cd5a68d5039f"},{"id":"254a7029-38c1-4bb5-bcfc-88ea43f448b5","theory_name":"Defined-factor reprogramming can reset cell state","theory_summary":null,"theory_text":"The inclusion of the 2006 defined-factor iPSC paper supports the foundational theory that cell state is not fixed: defined transcriptional inputs can causally reprogram adult differentiated cells into a more plastic, embryonic-like state. For Altos' longevity-relevant strategy, this implies that selected components of the reprogramming process may be used to reset aging-associated cellular programs.\n\nTestable predictions are that defined-factor interventions should reproducibly shift epigenetic and transcriptional state, reverse age-associated cell-state features, and allow controlled tuning between rejuvenation and unwanted loss of identity.","source_url":"https://www.cell.com/cell/fulltext/S0092-8674(06)00976-7","source_type":"publication","is_primary":false,"extracted_at":"2026-06-23 22:54:47.313319+00","owner":{"kind":"company","name":"Altos Labs","public_id":"DqlJyYuy","public_url":"https://eternalsearch.net/companies/DqlJyYuy"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":25,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":11},"detail_url":"https://eternalsearch.net/api/v1/theories/254a7029-38c1-4bb5-bcfc-88ea43f448b5"},{"id":"ecfac8aa-27ca-4f0b-ad34-35cf3cf42fee","theory_name":"Partial reprogramming reverses age-associated hallmarks","theory_summary":null,"theory_text":"A supplied mechanistic foundation for Altos' cellular rejuvenation program is that transient or partial reprogramming can ameliorate age-associated cellular and tissue hallmarks without necessarily driving cells all the way to pluripotency. The causal claim is that aspects of cellular aging are plastic and can be reset by controlled exposure to reprogramming factors.\n\nTestable predictions are that partial reprogramming should reduce molecular and functional markers of aging in vivo, improve tissue regeneration or function, and do so while preserving useful cell identity rather than producing full dedifferentiation or tumor-like growth.","source_url":"https://www.cell.com/cell/fulltext/S0092-8674(16)31664-6","source_type":"publication","is_primary":false,"extracted_at":"2026-06-23 22:54:47.297408+00","owner":{"kind":"company","name":"Altos Labs","public_id":"DqlJyYuy","public_url":"https://eternalsearch.net/companies/DqlJyYuy"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":25,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":11},"detail_url":"https://eternalsearch.net/api/v1/theories/ecfac8aa-27ca-4f0b-ad34-35cf3cf42fee"},{"id":"3873b639-b2a9-4240-bfb9-caa1cb8b61cc","theory_name":"Aging as repairable cellular and molecular damage","theory_summary":null,"theory_text":"FightAging!'s central causal theory is that aging is driven by accumulated root-cause damage, including cross-links, extracellular amyloid buildup, adaptive immune failure, lysosomal decline, mitochondrial DNA damage, nuclear DNA damage, and senescent cell accumulation. The proposed intervention logic is rejuvenation biotechnology: therapies should repair, remove, replace, or reverse these damage categories rather than only modulating downstream symptoms.\n\nIf this theory is correct, interventions that directly repair these damage classes should produce measurable improvements in healthspan, disease resistance, tissue function, and ultimately lifespan, while purely symptomatic approaches should have smaller or less durable effects.","source_url":"https://www.fightaging.org/archives/2015/12/major-mouse-testing-program-launches/","source_type":"company_website","is_primary":true,"extracted_at":"2026-06-22 08:43:32.684714+00","owner":{"kind":"company","name":"FightAging!","public_id":"K3FwhHxo","public_url":"https://eternalsearch.net/companies/K3FwhHxo"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":1,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/3873b639-b2a9-4240-bfb9-caa1cb8b61cc"},{"id":"55408121-2f86-41ab-9f78-389cf0c7db8f","theory_name":"Partial reprogramming can reverse age-associated cellular hallmarks","theory_summary":null,"theory_text":"Altos Labs' core causal theory is that cellular aging is at least partly driven by reversible cell-state changes, and that partial cellular reprogramming can restore a more youthful, resilient cellular state without erasing cell identity. The mechanism implied by the supplied material is that defined reprogramming-factor biology can reset age-associated cellular features enough to improve cell health and stress resistance, while avoiding full dedifferentiation into pluripotency.\n\nA testable prediction is that partial reprogramming interventions should reduce molecular and functional hallmarks of aging in vivo, improve cellular resistance to disease-associated stressors, and preserve tissue identity and function. The supplied 2016 Cell publication directly supports the claim that partial reprogramming can ameliorate age-associated hallmarks in vivo.","source_url":"https://www.cell.com/cell/fulltext/S0092-8674(16)31664-6","source_type":"publication","is_primary":true,"extracted_at":"2026-06-22 01:02:14.270768+00","owner":{"kind":"company","name":"Altos Labs","public_id":"DqlJyYuy","public_url":"https://eternalsearch.net/companies/DqlJyYuy"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":25,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":9},"detail_url":"https://eternalsearch.net/api/v1/theories/55408121-2f86-41ab-9f78-389cf0c7db8f"},{"id":"0f3ea062-a195-4b2b-9517-ead31a7850ed","theory_name":"Genome-engineered porcine organs can replace failed human organs","theory_summary":null,"theory_text":"eGenesis' central causal theory is that organ failure can be treated by transplanting porcine organs that have been genetically engineered to be more compatible with human recipients. If multiplex genome edits can reduce xenogeneic immune injury, infectious risk, and physiologic incompatibility, then engineered porcine kidneys, hearts, and livers should function as life-sustaining organ replacements or bridges for patients with end-stage organ disease.\n\nTestable predictions include sustained xenograft perfusion and organ-specific function in recipients, reduced acute rejection relative to unmodified pig organs, manageable immunosuppression requirements, and clinically meaningful survival or bridge-to-allotransplantation outcomes in kidney, heart, and liver failure settings.","source_url":"https://egenesisbio.com/pipeline","source_type":"company_website","is_primary":true,"extracted_at":"2026-06-20 03:27:53.711459+00","owner":{"kind":"company","name":"eGenesis","public_id":"2hKjLENP","public_url":"https://eternalsearch.net/companies/2hKjLENP"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":12,"foundational_alignment_count":0,"project_count":5,"reasoning_node_count":19},"detail_url":"https://eternalsearch.net/api/v1/theories/0f3ea062-a195-4b2b-9517-ead31a7850ed"},{"id":"ec2e9e8a-f10c-4e50-9ae0-1afbb4136656","theory_name":"Circulating factors can rapidly induce or reverse human tissue aging programs","theory_summary":null,"theory_text":"The human microphysiological aging work associated with Dr. Irina Conboy's scientific program proposes that factors present in human serum can drive aging or rejuvenation signatures in human tissues. In the reported white-adipose-tissue/liver microphysiological system, heterochronic human serum produced aging-associated functional and molecular hallmarks, including gerontic gene-expression shifts and oxidative DNA damage, within days.\n\nThe testable prediction is that aged or rejuvenated serum environments should reproducibly induce corresponding molecular and functional aging states in human tissue models, and that anti-geronic interventions should prevent or reverse those serum-induced aging signatures.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41882175/","source_type":"publication","is_primary":false,"extracted_at":"2026-06-14 05:32:36.884529+00","owner":{"kind":"company","name":"Generation Lab","public_id":"iR7uQVY9","public_url":"https://eternalsearch.net/companies/iR7uQVY9"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":10},"detail_url":"https://eternalsearch.net/api/v1/theories/ec2e9e8a-f10c-4e50-9ae0-1afbb4136656"},{"id":"fb33dfa8-e7b8-4092-9593-23e58c75071d","theory_name":"Engineered kidney xenotransplantation can restore renal function in kidney failure","theory_summary":null,"theory_text":"For EGEN-2784 and the kidney program, the theory is that a genetically engineered porcine kidney can substitute for a failed human kidney closely enough to sustain life and improve health in patients with end-stage kidney disease. By providing a functioning graft when human donor kidneys are unavailable, the intervention should address uremia and the morbidity of chronic kidney failure.\n\nTestable predictions include post-transplant kidney function, reduced dependence on dialysis, manageable rejection and infection risk, and clinical outcomes sufficient to support the Phase 1/2/3 trial enabled by FDA IND clearance.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39927618/","source_type":"publication","is_primary":false,"extracted_at":"2026-06-08 20:28:07.524482+00","owner":{"kind":"company","name":"eGenesis","public_id":"2hKjLENP","public_url":"https://eternalsearch.net/companies/2hKjLENP"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":12,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/fb33dfa8-e7b8-4092-9593-23e58c75071d"},{"id":"08bf8fda-7a64-4cdf-bf22-ca90bed6fdf0","theory_name":"Partial reprogramming can reverse age-related cellular state","theory_summary":null,"theory_text":"Rejuvenate Bio's partial-reprogramming theory is that aging reflects chronic dysregulation of cellular processes and epigenetic or gene-regulatory state, and that controlled expression of Yamanaka-factor subsets such as OSK can push aged cells toward a younger, healthier functional state without fully dedifferentiating them. In aged mice, systemic AAV delivery of an inducible OSK system is presented as a way to extend remaining lifespan and improve frailty; in human keratinocytes, exogenous OSK expression is linked to epigenetic markers of age reversal.\n\nTestable predictions are that inducible OSK gene therapy should extend lifespan, improve frailty or healthspan scores, and shift molecular aging markers toward younger profiles, while preserving enough cellular identity and safety control to avoid uncontrolled reprogramming.","source_url":"https://doi.org/10.1089/cell.2023.0072","source_type":"publication","is_primary":false,"extracted_at":"2026-06-02 20:06:00.37713+00","owner":{"kind":"company","name":"Rejuvenate Bio","public_id":"SSkLrdOl","public_url":"https://eternalsearch.net/companies/SSkLrdOl"},"evaluation":{"popperian_sum":33,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":9,"dimensions":{"ambition":9,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/08bf8fda-7a64-4cdf-bf22-ca90bed6fdf0"},{"id":"789a07fb-33cd-42d4-8edd-e9e3f957a21f","theory_name":"Pan-KRAS inhibition suppresses KRAS-driven cancers","theory_summary":null,"theory_text":"BridgeBio Oncology's BBO-11818 theory is that oncogenic KRAS mutants drive tumor growth through effector engagement and MAPK signaling, and that a noncovalent pan-KRAS inhibitor can bind multiple mutant KRAS proteins in both GDP-bound and GTP-bound states. Binding in the Switch-II/Helix 3 pocket is proposed to induce conformations incompatible with effector binding.\n\nTestable predictions are that BBO-11818 should selectively inhibit MAPK signaling and cell viability in KRAS-driven cancer models, produce tumor regressions in KRAS-mutant xenografts, and potentially improve outcomes in KRAS-mutant colorectal, pancreatic, lung, and related cancers, including in combinations with anti-PD-1, anti-EGFR, or PI3Kalpha-pathway agents.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41790032/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 13:02:48.319512+00","owner":{"kind":"company","name":"Eidos Therapeutics","public_id":"KJEsxKQd","public_url":"https://eternalsearch.net/companies/KJEsxKQd"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":13,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":18},"detail_url":"https://eternalsearch.net/api/v1/theories/789a07fb-33cd-42d4-8edd-e9e3f957a21f"},{"id":"dfa2484a-4928-48c4-b616-6b936faf4ad6","theory_name":"Greater stabilization should help both wild-type and variant ATTR-CM","theory_summary":null,"theory_text":"BridgeBio's acoramidis clinical rationale includes the claim that both age-related wild-type ATTR-CM and hereditary variant ATTR-CM arise from TTR destabilization, with variant TTR often being less stable and associated with worse outcomes. A stronger stabilizer should therefore be beneficial across wild-type and variant disease, including higher-risk variants such as p.Val142Ile.\n\nTestable predictions are that acoramidis should produce clinical benefit in both ATTRwt-CM and ATTRv-CM groups, with reductions in mortality and cardiovascular hospitalization and consistent effects across variant subgroups.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41205147/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 13:02:48.307477+00","owner":{"kind":"company","name":"Eidos Therapeutics","public_id":"KJEsxKQd","public_url":"https://eternalsearch.net/companies/KJEsxKQd"},"evaluation":{"popperian_sum":32,"premise_plausibility":9,"explanatory_power":8,"falsifiability":9,"ambition":6,"dimensions":{"ambition":6,"falsifiability":9,"explanatory_power":8,"premise_plausibility":9},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":13,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/dfa2484a-4928-48c4-b616-6b936faf4ad6"},{"id":"96d45419-af53-45ad-b1bf-d00646f6e917","theory_name":"Succinate prodrug neuroprotection reduces lesion formation and oxidative stress","theory_summary":null,"theory_text":"In mitochondrial complex I-related neurodegeneration, NV354 is proposed to protect the brain by restoring metabolic support and reducing downstream pathological consequences of mitochondrial dysfunction. In the Leigh syndrome mouse model, the reported causal chain is that succinate prodrug treatment modulates respiration and metabolic flexibility, lowers brain ROS, attenuates neuronal loss and glial activation, and prevents pathognomonic brain stem lesion development.\n\nTestable predictions are that NV354 should reduce ROS, neuroinflammation, neuronal loss, lesion burden, ataxia progression, and motor dysfunction in complex I-deficient neurodegenerative models, with possible translation to mitochondrial disease and related neurodegenerative states involving complex I impairment.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41704780/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 12:36:21.021237+00","owner":{"kind":"company","name":"Abliva","public_id":"Bqh0AdzI","public_url":"https://eternalsearch.net/companies/Bqh0AdzI"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":22},"detail_url":"https://eternalsearch.net/api/v1/theories/96d45419-af53-45ad-b1bf-d00646f6e917"},{"id":"30e5c45b-35a3-47b4-baec-f98bac5700b5","theory_name":"CNS-penetrant enzyme replacement addresses neuronopathic lysosomal storage disease","theory_summary":null,"theory_text":"Denali's programs in mucopolysaccharidosis and related lysosomal storage disorders imply the theory that conventional enzyme replacement is limited by inadequate CNS delivery, leaving neuronopathic disease mechanisms insufficiently treated. Coupling enzyme replacement to a barrier-crossing delivery approach should provide enzyme activity in the brain as well as the periphery, improving biochemical and clinical outcomes in disorders such as Hunter syndrome and Sanfilippo syndrome type A.\n\nTestable predictions include CNS exposure after intravenous dosing, pharmacodynamic correction of lysosomal disease biomarkers, and improvement or stabilization of neurological and systemic disease measures compared with enzyme replacement that does not effectively cross the blood-brain barrier.","source_url":"https://denalitherapeutics.com/product-and-pipeline#pipeline","source_type":"company_website","is_primary":false,"extracted_at":"2026-07-02 11:06:56.578707+00","owner":{"kind":"company","name":"Denali Therapeutics","public_id":"tX87Eqsp","public_url":"https://eternalsearch.net/companies/tX87Eqsp"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":4,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":12},"detail_url":"https://eternalsearch.net/api/v1/theories/30e5c45b-35a3-47b4-baec-f98bac5700b5"},{"id":"96414a1e-344c-4e1c-91a9-ed10068d9fd5","theory_name":"TREM2 agonism restores disease-modifying microglial function","theory_summary":null,"theory_text":"Denali-linked TREM2 research supports the theory that TREM2 is a central regulator of microglial state in Alzheimer's disease-relevant biology, and that activating TREM2 can improve microglial metabolic capacity, lipid handling, and phagocytic function. Because TREM2 loss-of-function variants increase late-onset Alzheimer's disease risk, therapeutic TREM2 agonism is proposed to shift microglia toward a state better able to respond to amyloid pathology and neurodegenerative stress.\n\nTestable predictions include increased microglial oxidative phosphorylation, redox and energetic signatures, cholesterol homeostasis, and phagocytic capacity after TREM2 activation, with therapeutic response depending on the baseline level of TREM2 expression in microglia.","source_url":"https://doi.org/10.1038/s41467-026-68706-8","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 11:06:56.556356+00","owner":{"kind":"company","name":"Denali Therapeutics","public_id":"tX87Eqsp","public_url":"https://eternalsearch.net/companies/tX87Eqsp"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":4,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":17},"detail_url":"https://eternalsearch.net/api/v1/theories/96414a1e-344c-4e1c-91a9-ed10068d9fd5"},{"id":"862d31d2-d468-40a6-a64f-eecfa4d5d2f0","theory_name":"Barrier-crossing biotherapeutic delivery to the CNS","theory_summary":null,"theory_text":"Denali's TransportVehicle platform is based on the causal theory that poor delivery of large-molecule therapeutics across the blood-brain barrier limits treatment of neurodegenerative and other CNS diseases. By engineering large molecules to engage endogenous transport systems such as transferrin receptor or CD98 heavy chain, therapeutics should achieve higher CNS exposure and broader parenchymal cell distribution than conventional IgG-like molecules.\n\nA testable prediction is that TransportVehicle-enabled molecules will show enhanced brain and spinal cord exposure, broader parenchymal cell-type distribution, and distinct biodistribution profiles versus non-transported controls, enabling biologic mechanisms that would otherwise be inaccessible in CNS disease.","source_url":"https://doi.org/10.1038/s41467-025-57108-x","source_type":"publication","is_primary":true,"extracted_at":"2026-07-02 11:06:56.539173+00","owner":{"kind":"company","name":"Denali Therapeutics","public_id":"tX87Eqsp","public_url":"https://eternalsearch.net/companies/tX87Eqsp"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":4,"foundational_alignment_count":0,"project_count":4,"reasoning_node_count":12},"detail_url":"https://eternalsearch.net/api/v1/theories/862d31d2-d468-40a6-a64f-eecfa4d5d2f0"},{"id":"081ea472-3f3f-4083-a883-d397a07217c4","theory_name":"Telomerase-activated telomere damage in cancer cells","theory_summary":null,"theory_text":"MAIA's core theory is that telomerase-positive cancer cells can be selectively attacked by using a telomerase substrate precursor such as ateganosine/THIO. Telomerase incorporates the agent into telomeres, producing rapid telomere dysfunction and DNA damage in malignant cells while sparing telomerase-silent normal cells. The expected causal effect is selective cancer-cell death or loss of proliferative capacity in tumors that depend on telomerase for continued replication.\n\nTestable predictions are that telomerase-positive tumors should show telomere-associated DNA damage after treatment, reduced viability or tumor growth, and greater sensitivity than telomerase-negative or telomerase-silent normal cells. Clinically, this predicts activity in telomerase-positive cancers such as advanced/metastatic NSCLC.","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/26425659","source_type":"publication","is_primary":true,"extracted_at":"2026-07-02 08:51:16.211244+00","owner":{"kind":"company","name":"MAIA","public_id":"cjQt04HA","public_url":"https://eternalsearch.net/companies/cjQt04HA"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":10,"foundational_alignment_count":0,"project_count":4,"reasoning_node_count":14},"detail_url":"https://eternalsearch.net/api/v1/theories/081ea472-3f3f-4083-a883-d397a07217c4"},{"id":"03acdb06-e52d-4c2d-9b9f-6c5df551e93b","theory_name":"Human resilience biology reveals drug targets missed by models","theory_summary":null,"theory_text":"Muna's MiND-MAP platform is based on the theory that human brain tissue from people with Alzheimer’s pathology, dementia, and pathology-resilient cognition contains causal molecular signatures of vulnerability and neuroprotection. By combining spatial transcriptomics, single-nucleus profiling, genetics, protein-interaction data, structural biology, computational chemistry, and cell-based screening, Muna aims to identify targets whose modulation should reproduce resilience-associated biology or block vulnerability-associated biology.\n\nThe testable prediction is that genes and pathways distinguishing vulnerable from resilient human brains will nominate therapeutic targets that validate across human-derived cells, in vivo systems, and biomarker studies, and that compounds against those targets will better preserve brain function than targets chosen only from non-human models or pathology burden alone.","source_url":"https://www.youtube.com/watch?v=5aaCdk0bdEY","source_type":"interview","is_primary":false,"extracted_at":"2026-07-02 06:18:37.566004+00","owner":{"kind":"company","name":"Muna Therapeutics","public_id":"fbjiPG8M","public_url":"https://eternalsearch.net/companies/fbjiPG8M"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":8,"ambition":9,"dimensions":{"ambition":9,"falsifiability":8,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":12},"detail_url":"https://eternalsearch.net/api/v1/theories/03acdb06-e52d-4c2d-9b9f-6c5df551e93b"},{"id":"ae08eea0-c868-4968-871b-236312dcd051","theory_name":"Microglial state transitions determine dementia versus resilience","theory_summary":null,"theory_text":"Muna's resilience research is based on the theory that Alzheimer’s disease is shaped not only by amyloid-beta and tau burden, but by how microglia transition across pathological states at the amyloid-beta-tau interface. The cited Nature Medicine study reports a shift from early inflammatory plaque-induced gene programs to late antigen-presenting microglial phenotypes, with divergent patterns in people who develop dementia versus those who remain resilient despite pathology.\n\nThe causal implication is that specific microglial transition states can either permit progression from pathology to dementia or support preserved cognition despite amyloid-beta accumulation. A therapeutic that prevents harmful late-state coupling to tau, promotes resilience-associated microglial programs, or uncouples microglial activation from neurodegenerative pathology should improve healthspan-relevant brain function in aging individuals at risk for Alzheimer’s disease.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42243549/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 06:18:37.54592+00","owner":{"kind":"company","name":"Muna Therapeutics","public_id":"fbjiPG8M","public_url":"https://eternalsearch.net/companies/fbjiPG8M"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":8,"ambition":9,"dimensions":{"ambition":9,"falsifiability":8,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":13},"detail_url":"https://eternalsearch.net/api/v1/theories/ae08eea0-c868-4968-871b-236312dcd051"},{"id":"e0d54a08-af1f-4b64-86f4-302bd732da2b","theory_name":"Hypoimmune CAR-T cells provide durable immune effector activity without rejection","theory_summary":null,"theory_text":"For cancer and B-cell mediated autoimmune disease, Sana's causal theory is that hypoimmune allogeneic CAR-T cells can avoid host rejection while retaining antigen-directed cytotoxic function. If immune-evasive CAR-T cells persist longer in immunocompetent recipients, they should provide sustained depletion of pathogenic or malignant B cells and improve durability compared with allogeneic cells that are rapidly rejected.\n\nTestable predictions include persistence of hypoimmune CAR-T cells in allogeneic hosts, antigen-specific killing of CD19- or BCMA-expressing cells, lasting tumor control or B-cell depletion, and reduced immunogenicity relative to conventional allogeneic CAR-T approaches.","source_url":"https://sana.com/app/uploads/2026/03/2023-Nature-Communications-Hu-et-al.pdf","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 05:10:20.399279+00","owner":{"kind":"company","name":"Sana Biotechnology","public_id":"be5enfPo","public_url":"https://eternalsearch.net/companies/be5enfPo"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":6,"reasoning_node_count":10},"detail_url":"https://eternalsearch.net/api/v1/theories/e0d54a08-af1f-4b64-86f4-302bd732da2b"},{"id":"a6491edd-75b4-414f-a40d-1d9979ddccbb","theory_name":"Hypoimmune engineering enables off-the-shelf allogeneic cell medicines","theory_summary":null,"theory_text":"Sana's broader hypoimmune theory is that immune rejection is a central barrier preventing scalable allogeneic cell therapies, and that engineered immune-evasive cells can survive long term across donor-recipient mismatch. By reducing recognition by host immune systems, induced pluripotent stem cell-derived products, primary islets, or engineered immune cells should persist without patient-specific manufacturing or intensive immunosuppression.\n\nTestable predictions include long-term survival of hypoimmune cells in fully immunocompetent allogeneic animals, reduced immune clearance compared with non-engineered cells, retained therapeutic function after transplantation, and feasibility of broadly available cell-replacement or cell-therapy products.","source_url":"https://sana.com/app/uploads/2026/03/2023-Nature-Biotechnology-Hu-et-al.pdf","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 05:10:20.380051+00","owner":{"kind":"company","name":"Sana Biotechnology","public_id":"be5enfPo","public_url":"https://eternalsearch.net/companies/be5enfPo"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/a6491edd-75b4-414f-a40d-1d9979ddccbb"},{"id":"515e0850-a4cb-45f6-9e69-899517f0aae6","theory_name":"Hypoimmune beta-cell replacement restores insulin regulation without chronic immunosuppression","theory_summary":null,"theory_text":"Sana's hypoimmune cell-replacement theory is that engineered allogeneic pancreatic beta cells or islets can replace missing or autoimmune-destroyed beta-cell function in type 1 diabetes while avoiding both alloimmune rejection and recurrent autoimmunity. If transplanted cells are made hypoimmune, they should survive in an immunocompetent host without systemic immunosuppression, secrete insulin in response to glucose, and reduce or eliminate dependence on exogenous insulin.\n\nTestable predictions include durable graft survival after allogeneic transplantation, maintained glucose-responsive insulin production, improved glycemic control or insulin independence, and absence of clinically meaningful immune rejection despite no chronic immunosuppression.","source_url":"https://sana.com/app/uploads/2026/03/2025-NEJM-Carlsson-et-al.pdf","source_type":"publication","is_primary":true,"extracted_at":"2026-07-02 05:10:20.336783+00","owner":{"kind":"company","name":"Sana Biotechnology","public_id":"be5enfPo","public_url":"https://eternalsearch.net/companies/be5enfPo"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":14},"detail_url":"https://eternalsearch.net/api/v1/theories/515e0850-a4cb-45f6-9e69-899517f0aae6"},{"id":"85aaccb5-84de-4441-834c-c031ecfe63ba","theory_name":"Distinct alpha-synuclein inclusion subtypes determine neuronal survival","theory_summary":null,"theory_text":"Yumanity-associated inclusionopathy models support a theory that alpha-synuclein inclusions are not uniformly harmful; rather, different molecular subtypes have different consequences for neuronal survival. In particular, p62-positive inclusions may be comparatively neuroprotective, while dynamic lipid-rich inclusions may be neurotoxic, and transitions or fusion events between inclusion classes can alter cell fate.\n\nThis theory predicts that single-inclusion tracking in human CNS cells should distinguish inclusion classes with different survival outcomes, and that modifying inclusion composition, lipid content, or fusion dynamics should change neuronal death risk. It also predicts that toxicity modifiers sequestered into inclusions, such as RNA-processing or actin-cytoskeleton regulators including RhoA, may causally contribute to degeneration.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39079530/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-02 04:01:33.176323+00","owner":{"kind":"company","name":"Yumanity Therapeutics","public_id":"Kk7G9GtP","public_url":"https://eternalsearch.net/companies/Kk7G9GtP"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":8,"falsifiability":9,"ambition":7,"dimensions":{"ambition":7,"falsifiability":9,"explanatory_power":8,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":3,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":22},"detail_url":"https://eternalsearch.net/api/v1/theories/85aaccb5-84de-4441-834c-c031ecfe63ba"},{"id":"bc0cb700-e049-40dd-b655-9e48432ea1a6","theory_name":"SCD inhibition reduces alpha-synuclein lipid toxicity","theory_summary":null,"theory_text":"Yumanity's lead mechanistic theory was that aberrant alpha-synuclein toxicity in Parkinson's disease and related synucleinopathies is driven in part by disrupted lipid biology, especially lipid- and vesicle-rich alpha-synuclein inclusions and abnormal alpha-synuclein membrane interactions. Inhibiting stearoyl-CoA desaturase (SCD) should lower monounsaturated fatty acid production, alter fatty-acid desaturation state, and thereby reduce toxic alpha-synuclein conformations, membrane association, phosphorylation, and aggregation.\n\nTestable predictions include that a brain-penetrant SCD inhibitor such as YTX-7739 should reduce fatty-acid desaturation indices in brain, rescue alpha-synuclein-mediated neuronal death in cellular models, lower pathological pS129 and protease-resistant alpha-synuclein in animal models, restore healthier alpha-synuclein tetramer-to-monomer balance, preserve dopaminergic neurons, and improve or prevent motor phenotypes in Parkinson's disease models.","source_url":"https://pubmed.ncbi.nlm.nih.gov/35445353/","source_type":"publication","is_primary":true,"extracted_at":"2026-07-02 04:01:33.155213+00","owner":{"kind":"company","name":"Yumanity Therapeutics","public_id":"Kk7G9GtP","public_url":"https://eternalsearch.net/companies/Kk7G9GtP"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":3,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":23},"detail_url":"https://eternalsearch.net/api/v1/theories/bc0cb700-e049-40dd-b655-9e48432ea1a6"},{"id":"11a87541-c9e3-4fa0-a4e3-371c45de3da1","theory_name":"VDAC1 oligomerization inhibition blocks mitochondrial cell death","theory_summary":null,"theory_text":"X-tosis's VDAC1-modulating compounds are based on the theory that VDAC1 overexpression and oligomerization act as a shared upstream driver of mitochondria-linked programmed cell death pathways, including apoptosis, pyroptosis, and ferroptosis. Inhibiting VDAC1 oligomerization should therefore protect vulnerable neurons by blocking multiple cell-death programs at once rather than targeting only one downstream pathway.\n\nTestable predictions include reduced neuronal apoptosis, pyroptosis, and ferroptosis after treatment with XTS/VBIT-like compounds; preservation of mitochondrial integrity under neurodegenerative stress; and reduced neuronal loss in models of Alzheimer's disease, Parkinson's disease, ALS, or related disorders.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41964801/","source_type":"publication","is_primary":true,"extracted_at":"2026-07-02 03:44:58.287612+00","owner":{"kind":"company","name":"X-tosis","public_id":"Pqv4id3w","public_url":"https://eternalsearch.net/companies/Pqv4id3w"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":6,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":14},"detail_url":"https://eternalsearch.net/api/v1/theories/11a87541-c9e3-4fa0-a4e3-371c45de3da1"},{"id":"3e6f80e1-d0dd-46b9-bcd5-8f316ed17ed7","theory_name":"Target-induced clustering activates TRIM21 degradation","theory_summary":null,"theory_text":"A more specific mechanistic theory is that multimeric or aggregated targets are especially suitable for TRIM21-based degradation because target-induced clustering activates the TRIM21/Trim-Away pathway. Aggregated disease proteins provide a clustered scaffold that can increase local recruitment and activation of TRIM21, enabling selective degradation of pathological assemblies over monomeric proteins.\n\nThis predicts that degrader activity should be stronger against multimeric or aggregated targets than against isolated monomers, and that chemically induced proximity to TRIM21 should be sufficient to trigger degradation of multimeric protein assemblies. It also predicts that degrader design can tune selectivity by requiring aggregate-dependent avidity or clustering.","source_url":"https://pubmed.ncbi.nlm.nih.gov/33633400/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 23:57:08.470708+00","owner":{"kind":"company","name":"TrimTech Therapeutics","public_id":"uTs7cSqa","public_url":"https://eternalsearch.net/companies/uTs7cSqa"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":5,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/3e6f80e1-d0dd-46b9-bcd5-8f316ed17ed7"},{"id":"11f769b8-a765-42e7-881a-ec3d295c0673","theory_name":"TRIM21 intracellular immunity can be repurposed against neurodegenerative aggregates","theory_summary":null,"theory_text":"TRIMTECH's platform builds on the biological theory that TRIM21 is a cytosolic antibody receptor and E3 ubiquitin ligase whose natural role is to recognize antibody-bound intracellular targets and route them to degradation. If small molecules can mimic or replace antibody-mediated target engagement, this intracellular immune degradation pathway can be redirected toward disease-associated protein aggregates.\n\nA testable prediction is that degradation efficacy should depend on TRIM21 recruitment and downstream ubiquitin-proteasome machinery. Loss or inhibition of TRIM21, proteasomal degradation, or required cofactors such as p97/VCP would be expected to reduce target clearance, while productive target clustering should enhance degradation.","source_url":"https://pubmed.ncbi.nlm.nih.gov/21045130/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 23:57:08.454247+00","owner":{"kind":"company","name":"TrimTech Therapeutics","public_id":"uTs7cSqa","public_url":"https://eternalsearch.net/companies/uTs7cSqa"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":17},"detail_url":"https://eternalsearch.net/api/v1/theories/11f769b8-a765-42e7-881a-ec3d295c0673"},{"id":"433a838d-9a20-4278-94b0-4d9ac6ccff9b","theory_name":"Aggregate-selective tau removal for Alzheimer's disease","theory_summary":null,"theory_text":"For Alzheimer's disease and tauopathy-related programs, the implied mechanism is that pathological tau assemblies contribute causally to neurodegeneration, and that clustering-activated or aggregate-selective degraders can exploit the multivalent structure of tau aggregates to remove pathological tau preferentially. By recruiting TRIM21-mediated ubiquitin-proteasome degradation to aggregated tau, the intervention should reduce toxic tau species without broadly eliminating normal soluble tau.\n\nTestable predictions include selective depletion of aggregated/pathological tau, reduced seeded tau aggregation, lower tau pathology propagation, and improved neuronal or behavioral phenotypes in tauopathy models. The theory is supported by publications describing aggregate-selective removal of pathological tau and co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39208111/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 23:57:08.439812+00","owner":{"kind":"company","name":"TrimTech Therapeutics","public_id":"uTs7cSqa","public_url":"https://eternalsearch.net/companies/uTs7cSqa"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":7,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/433a838d-9a20-4278-94b0-4d9ac6ccff9b"},{"id":"35e63cb6-55c3-4e43-b720-c9aa43f38903","theory_name":"Dopaminergic neuron replacement for Parkinson's disease","theory_summary":null,"theory_text":"TreeFrog's Parkinson's program is based on the causal claim that replacing the primary dysfunctional cell population in Parkinson's disease, A9 dopaminergic neurons, can restore dopaminergic input to host striatal circuits and thereby improve motor function. Its 3D hiPSC-derived neural microtissues are intended to survive transplantation, mature into dopaminergic neurons, project into host striatum, and produce dose-dependent behavioral recovery.\n\nTestable predictions are that transplanted microtissues will show human dopaminergic neuron survival, host-striatum innervation, and improvement in Parkinsonian motor phenotypes proportional to graft dose; in the cited rat model, this was reported as normalization of rotational bias and full behavioral recovery 16 weeks after transplantation.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39353832/","source_type":"publication","is_primary":true,"extracted_at":"2026-07-01 23:31:40.910552+00","owner":{"kind":"company","name":"Treefrog Therapeutics","public_id":"UpiLcNQS","public_url":"https://eternalsearch.net/companies/UpiLcNQS"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":18},"detail_url":"https://eternalsearch.net/api/v1/theories/35e63cb6-55c3-4e43-b720-c9aa43f38903"},{"id":"bb2d871d-0e68-47d1-bd4a-15d9aff78087","theory_name":"Supercooling preserves organ viability by slowing biological time","theory_summary":null,"theory_text":"Sylvatica's core causal theory is that lowering organs and tissues into high-subzero or subzero non-frozen states can slow biological processes that normally degrade transplantable tissue outside the body. By controlling biological time through cryobanking and supercooling, the platform should extend preservation windows while maintaining organ quality.\n\nTestable predictions include longer viable storage times for human livers or other organs versus conventional cold storage, preserved functional markers after rewarming or perfusion, and successful transplantation outcomes after extended preservation intervals.","source_url":null,"source_type":"manual_entry","is_primary":true,"extracted_at":"2026-07-01 20:13:22.174306+00","owner":{"kind":"company","name":"Sylvatica Biotech","public_id":"aCthbGG1","public_url":"https://eternalsearch.net/companies/aCthbGG1"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":1,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":11},"detail_url":"https://eternalsearch.net/api/v1/theories/bb2d871d-0e68-47d1-bd4a-15d9aff78087"},{"id":"ec6d827e-ebe9-4317-83d6-f9edc87e642b","theory_name":"Young blood or plasma signals can reverse age-related tissue dysfunction","theory_summary":null,"theory_text":"Rejenevie's cited parabiosis and young-plasma literature supports the theory that circulating youthful factors can reverse functional impairments in aged tissues, including cognitive and synaptic decline. This implies that aging phenotypes are not solely cell-intrinsic or irreversible, but are partly maintained by modifiable systemic signals.\n\nTestable predictions are that exposure to young blood, young plasma, or identified youthful plasma factors should improve age-sensitive phenotypes such as synaptic plasticity, cognition, tissue repair, or survival in aged animal models, while aged systemic environments should impair young or rejuvenated cells.","source_url":"https://www.rejenevie.com/wp-content/uploads/2019/04/Villeda-2014.pdf","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 17:18:46.955175+00","owner":{"kind":"company","name":"Rejenevie Therapeutics","public_id":"8XtiGWWa","public_url":"https://eternalsearch.net/companies/8XtiGWWa"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":8,"ambition":9,"dimensions":{"ambition":9,"falsifiability":8,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":0,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/ec6d827e-ebe9-4317-83d6-f9edc87e642b"},{"id":"2300cbb7-b82e-40c6-b7ce-4cde0dd0bd00","theory_name":"Microglial NLRP3 activation drives synucleinopathy progression","theory_summary":null,"theory_text":"For Parkinson's disease and multiple system atrophy models, the causal theory is that sustained NLRP3 inflammasome activation in disease-associated reactive microglia is a shared pathogenic driver of α-synucleinopathy progression. Chronic oral dapansutrile should reprogram inflammatory microglial states, reduce α-synuclein pathology and gliosis, and slow nigral neurodegeneration.\n\nThis theory predicts improved motor performance, reduced α-synuclein inclusions, attenuated gliosis, preservation of nigral neurons, reversal of disease-associated microglial transcriptional signatures, and correlated changes in translational blood biomarkers such as IL-18 and neurofilament light chain.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41620763/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 16:38:36.108394+00","owner":{"kind":"company","name":"Olatec","public_id":"fdaPR92A","public_url":"https://eternalsearch.net/companies/fdaPR92A"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":8,"falsifiability":9,"ambition":7,"dimensions":{"ambition":7,"falsifiability":9,"explanatory_power":8,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":5,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":22},"detail_url":"https://eternalsearch.net/api/v1/theories/2300cbb7-b82e-40c6-b7ce-4cde0dd0bd00"},{"id":"612267f7-0ec3-4f88-b352-7baf709774bb","theory_name":"SAP depletion enables amyloid clearance in systemic amyloidosis","theory_summary":null,"theory_text":"Pentraxin's systemic amyloidosis program is based on the claim that serum amyloid P component (SAP) is a pathogenic constituent of amyloid deposits and that depleting circulating SAP with CPHPC/miridesap can expose deposited SAP-associated amyloid to immune clearance. Adding the anti-SAP antibody dezamizumab is intended to target residual SAP in amyloid deposits and trigger removal of amyloid material from affected tissues.\n\nTestable predictions include reduced circulating SAP after miridesap, antibody localization to amyloid deposits, reduced amyloid burden in organs, and clinical improvement or stabilization in systemic amyloidosis patients if amyloid clearance is achieved.","source_url":"https://pentraxin.wordpress.com/rd-programs/","source_type":"company_website","is_primary":true,"extracted_at":"2026-07-01 15:39:08.46909+00","owner":{"kind":"company","name":"Pentraxin Therapeutics","public_id":"Hct0hiK3","public_url":"https://eternalsearch.net/companies/Hct0hiK3"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":1,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/612267f7-0ec3-4f88-b352-7baf709774bb"},{"id":"2970e9b0-7cb1-47c4-b8a4-c6fedb0bf7ac","theory_name":"Inhibitory neuron transplantation reopens or reshapes cortical plasticity","theory_summary":null,"theory_text":"A broader regenerative mechanism is that immature inhibitory interneuron transplantation can induce cortical plasticity after grafting into the postnatal or adult brain. The causal claim is that transplanted interneuron precursors do not only add inhibition, but can reorganize host circuit function during their maturation window, creating an opportunity to correct dysfunctional neural networks. This predicts time-dependent changes in cortical inhibition and plasticity after transplant, with functional effects emerging as grafted cells mature and synaptically integrate.","source_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377860/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 14:47:42.832324+00","owner":{"kind":"company","name":"Neurona Therapeutics","public_id":"7KflaKWD","public_url":"https://eternalsearch.net/companies/7KflaKWD"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/2970e9b0-7cb1-47c4-b8a4-c6fedb0bf7ac"},{"id":"833554f7-f363-4de6-b9a0-1bc1e967a6d1","theory_name":"Spinal inhibitory interneuron grafts suppress neuropathic pain and autonomic dysfunction","theory_summary":null,"theory_text":"For spinal cord injury-related healthspan impairment, the causal theory is that loss or dysfunction of inhibitory signaling in spinal circuits contributes to central neuropathic pain and bladder dysfunction. Transplanted human stem cell-derived interneuron precursors are expected to integrate into injured spinal circuitry and restore local inhibitory control, reducing pathological pain signaling and improving bladder function. The testable prediction is that grafted inhibitory neurons should reduce behavioral pain measures and bladder dysfunction in injury models.","source_url":"https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30377-2","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 14:47:42.823478+00","owner":{"kind":"company","name":"Neurona Therapeutics","public_id":"7KflaKWD","public_url":"https://eternalsearch.net/companies/7KflaKWD"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/833554f7-f363-4de6-b9a0-1bc1e967a6d1"},{"id":"f9215b5d-8d9c-4031-a188-ee6bd160b431","theory_name":"Enhancing interneuron sodium-channel function can restore brain rhythms and cognition in Alzheimer's models","theory_summary":null,"theory_text":"A disease-modifying theory for age-related neurodegeneration is that impaired inhibitory interneuron function contributes causally to network-rhythm disruption and cognitive deficits in Alzheimer's disease. Transplanting interneurons engineered to overexpress Nav1.1 is proposed to strengthen interneuron excitability, restore abnormal brain rhythms, and improve cognition in an Alzheimer's mouse model. If the mechanism is correct, treated animals should show normalized oscillatory activity alongside cognitive improvement, not merely local cell survival.","source_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886814/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 14:47:42.813696+00","owner":{"kind":"company","name":"Neurona Therapeutics","public_id":"7KflaKWD","public_url":"https://eternalsearch.net/companies/7KflaKWD"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/f9215b5d-8d9c-4031-a188-ee6bd160b431"},{"id":"2f8036cf-7aac-46d2-968d-8ebdd9599866","theory_name":"GABAergic interneuron replacement restores inhibitory circuit balance in focal epilepsy","theory_summary":null,"theory_text":"Neurona's lead causal theory is that chronic focal epilepsy can be treated by delivering human medial ganglionic eminence-type GABAergic interneurons into the epileptic brain, where the cells survive, migrate, mature, form inhibitory synapses, secrete GABA, and restore excitation-inhibition balance in hyperexcitable temporal-lobe circuits. If correct, a single intracerebral administration of NRTX-1001 should reduce seizure frequency and abnormal epileptiform activity without requiring continuous systemic antiseizure drug exposure.","source_url":"https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(23)00296-5","source_type":"publication","is_primary":true,"extracted_at":"2026-07-01 14:47:42.786591+00","owner":{"kind":"company","name":"Neurona Therapeutics","public_id":"7KflaKWD","public_url":"https://eternalsearch.net/companies/7KflaKWD"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":9,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":20},"detail_url":"https://eternalsearch.net/api/v1/theories/2f8036cf-7aac-46d2-968d-8ebdd9599866"},{"id":"1465e314-c623-44ce-a2cb-ff32ac21a20a","theory_name":"Transcription factor combinations can causally drive cell fate conversion","theory_summary":null,"theory_text":"The MOGRIFY platform is based on the theory that cell identity is governed by transcription factor regulatory networks, and that a nonredundant set of transcription factors with high regulatory influence can convert one cell type into another. In this model, reprogramming is not random screening but a predictable intervention on the gene regulatory architecture that maintains or changes cell state.\n\nTestable predictions include: MOGRIFY-ranked transcription factors should be enriched for causal regulators of the target cell identity; introducing the predicted factor combinations should shift transcriptomic profiles toward the target cell type; and removing or perturbing key predicted factors should reduce conversion efficiency.","source_url":null,"source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 09:47:27.347836+00","owner":{"kind":"company","name":"Mogrify","public_id":"EHYlF0N5","public_url":"https://eternalsearch.net/companies/EHYlF0N5"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":4,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":15},"detail_url":"https://eternalsearch.net/api/v1/theories/1465e314-c623-44ce-a2cb-ff32ac21a20a"},{"id":"8b1b40ba-bea8-4b30-a0b5-442f2d98fc4d","theory_name":"Storable mitochondria enable scalable mitochondrial replacement therapy","theory_summary":null,"theory_text":"LUCA Science's platform theory is that functional mitochondria can be isolated, cryopreserved, thawed, formulated, and delivered while retaining enough membrane integrity, respiratory capacity, and biological activity to function as a biopharmaceutical agent. This addresses a practical limitation of mitochondrial transplantation, where conventional approaches require fresh tissue because isolated mitochondria are fragile.\n\nTestable predictions are that cryopreserved and thawed MRC-Q should retain membrane integrity, respiratory capacity, catalase activity, and therapeutic effects after storage, enabling reproducible dosing across disease models without requiring freshly isolated autologous mitochondria.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42284991/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 05:48:15.903164+00","owner":{"kind":"company","name":"Luca Science","public_id":"hs5FuNcl","public_url":"https://eternalsearch.net/companies/hs5FuNcl"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":3,"foundational_alignment_count":0,"project_count":3,"reasoning_node_count":19},"detail_url":"https://eternalsearch.net/api/v1/theories/8b1b40ba-bea8-4b30-a0b5-442f2d98fc4d"},{"id":"a72a6e8e-f9fa-4aa2-996c-324d526ad060","theory_name":"Mitochondria transfer treats inherited mitochondrial disease","theory_summary":null,"theory_text":"For Leigh syndrome and related inherited mitochondrial diseases, the causal theory is that delivery or transfer of healthy donor mitochondria can compensate for defective host mitochondrial metabolism. The provided Leigh syndrome study reports that wild-type bone marrow transplantation, isolated wild-type mitochondria, and human mitochondria improved disease phenotypes in Ndufs4-/- mice, while mitochondria from Ndufs4-/- mice did not improve neurological function.\n\nTestable predictions are that healthy mitochondria, but not disease-defective mitochondria, should extend lifespan, improve neurological function, increase energy expenditure, and reduce morbidity in mitochondrial disease models.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39223312/","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 05:48:15.871489+00","owner":{"kind":"company","name":"Luca Science","public_id":"hs5FuNcl","public_url":"https://eternalsearch.net/companies/hs5FuNcl"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":3,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":19},"detail_url":"https://eternalsearch.net/api/v1/theories/a72a6e8e-f9fa-4aa2-996c-324d526ad060"},{"id":"44c1b4a3-92d0-4006-9e9d-83dc1cf98cbc","theory_name":"Human disease-signature reversal predicts therapeutic benefit","theory_summary":null,"theory_text":"Gordian's Pythia-style transcriptomic analysis rests on the causal claim that interventions which push diseased single-cell transcriptomes away from human disease-specific molecular signatures are more likely to improve age-related disease biology. The mechanism is not merely biomarker association: perturbations are scored across disease domains such as fibrosis, inflammatory signaling, and tissue structure, then prioritized when they reverse molecular programs linked to pathology.\n\nThe prediction is that perturbations with favorable transcriptomic scores should produce measurable functional improvements in orthogonal human ex vivo systems, such as reduced soluble collagen in fibrotic lung slices or restored glycosaminoglycan in cartilage.","source_url":"https://www.biorxiv.org/content/10.64898/2026.02.26.708253v1","source_type":"publication","is_primary":false,"extracted_at":"2026-07-01 01:52:45.309301+00","owner":{"kind":"company","name":"Gordian Biotechnology","public_id":"VWDePCEM","public_url":"https://eternalsearch.net/companies/VWDePCEM"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":29,"foundational_alignment_count":0,"project_count":4,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/44c1b4a3-92d0-4006-9e9d-83dc1cf98cbc"},{"id":"c8386a70-34ed-49ea-a0e3-94065c12d250","theory_name":"Native diseased-tissue screening improves translation","theory_summary":null,"theory_text":"Gordian's central theory is that therapeutic targets for age-related diseases should be discovered and validated inside native diseased tissues, because organ architecture, cell-cell interactions, and disease microenvironments causally shape whether an intervention will work. Reductionist in vitro assays can miss these dependencies, while in vivo Mosaic Screening measures perturbation effects directly in living disease contexts.\n\nA testable prediction is that targets ranked by in vivo mosaic perturbation plus transcriptomic disease-signature reversal should be more likely to produce functional benefit in human-relevant validation systems than targets selected from simplified cell culture or single-pathway assumptions.","source_url":"https://www.biorxiv.org/content/10.64898/2026.02.26.708253v1","source_type":"publication","is_primary":true,"extracted_at":"2026-07-01 01:52:45.279912+00","owner":{"kind":"company","name":"Gordian Biotechnology","public_id":"VWDePCEM","public_url":"https://eternalsearch.net/companies/VWDePCEM"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":29,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":16},"detail_url":"https://eternalsearch.net/api/v1/theories/c8386a70-34ed-49ea-a0e3-94065c12d250"},{"id":"d2c10611-1f7b-4aaa-87ed-f4b9f437c9de","theory_name":"Intracellular frataxin replacement for Friedreich's ataxia","theory_summary":null,"theory_text":"Larimar's central causal theory is that Friedreich's ataxia pathology is driven by deficiency of frataxin, a mitochondrial protein, and that replacing human frataxin inside cells should modify disease biology. Nomlabofusp is designed as a recombinant cell-penetrating human frataxin fusion protein that enters cells and delivers frataxin to mitochondria in disease-relevant tissues such as dorsal root ganglia, heart, and skeletal muscle.\n\nTestable predictions are that subcutaneous nomlabofusp should increase human frataxin in affected tissues, show dose-dependent tissue exposure, and produce pharmacodynamic effects consistent with restored frataxin biology. In disease models, this should translate into improved cardiac function and survival; in patients, it should raise tissue frataxin and support downstream biomarker changes relevant to Friedreich's ataxia.","source_url":"https://pubmed.ncbi.nlm.nih.gov/40562976/","source_type":"publication","is_primary":true,"extracted_at":"2026-06-30 23:46:00.68325+00","owner":{"kind":"company","name":"Chondrial Therapeutics","public_id":"P8Xl7pIg","public_url":"https://eternalsearch.net/companies/P8Xl7pIg"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":8,"foundational_alignment_count":0,"project_count":2,"reasoning_node_count":14},"detail_url":"https://eternalsearch.net/api/v1/theories/d2c10611-1f7b-4aaa-87ed-f4b9f437c9de"},{"id":"917451e5-0e33-427b-85f0-8d3b8d6f43f4","theory_name":"Brain geometry constrains regional organization and biological patterning","theory_summary":null,"theory_text":"The geometry-based parcellation work proposes that the shape of brain structures causally influences regional organization across mammalian brains. The mechanistic claim is that brain geometry can shape spatial expression patterns of developmental molecules through a hierarchical reaction-diffusion-like process, producing conserved regional organization across species.\n\nTestable predictions include: geometry-derived parcellations should align with anatomical, functional, cellular, and molecular properties across species; the approach should generalize to species without existing brain atlases; and regions generated from geometry alone should be more internally homogeneous than many conventional parcellations.","source_url":"https://pubmed.ncbi.nlm.nih.gov/39975401/","source_type":"publication","is_primary":false,"extracted_at":"2026-06-30 17:31:02.155517+00","owner":{"kind":"company","name":"BrainKey","public_id":"i5is7u0H","public_url":"https://eternalsearch.net/companies/i5is7u0H"},"evaluation":{"popperian_sum":32,"premise_plausibility":8,"explanatory_power":7,"falsifiability":9,"ambition":8,"dimensions":{"ambition":8,"falsifiability":9,"explanatory_power":7,"premise_plausibility":8},"foundational_alignment_avg":null},"connections":{"cluster_slugs":[],"cluster_count":0,"endorsement_count":8,"foundational_alignment_count":0,"project_count":1,"reasoning_node_count":13},"detail_url":"https://eternalsearch.net/api/v1/theories/917451e5-0e33-427b-85f0-8d3b8d6f43f4"}],"pagination":{"total":2118,"limit":50,"offset":0,"has_more":true},"access_level":"public"}